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This study was to test the hypothesis that tetramethylpyrazine (TMP) protected against early brain injury after subarachnoid
hemorrhage (SAH) by affecting the mitochondrial-dependent caspase-3 apoptotic pathway. TMP was administrated after the rats’
prechiasmatic SAHmode. Animal neurobehavioral functionswere assessed and themitochondrialmorphology,mitochondrial and
cytoplasmic calcium, and mitochondrial membrane potential changes (Δ𝜓m) of the brain tissues were measured. The expressions
of cytoplasmic cytochrome c (cyt c), second mitochondria-derived activator of caspases (Smac), and cleaved caspase-3 B-cell
lymphoma 2 (bcl-2) in cells were determined and cellular apoptosis was detected. The treatment of TMP resulted in less apoptotic
cells and milder mitochondrial injury and potentially performed better in the neurobehavioral outcome compared to those with
saline. Also, TMP ameliorated calcium overload in mitochondria and cytoplasm and alleviated the decrease of Δ𝜓m. In addition,
TMP inhibited the expression of cytoplasmic cyt c, Smac, and cleaved caspase-3, yet it upregulated the expression of bcl-2. These
findings suggest that TMP exerts an antiapoptosis property in the SAH rat model and this is probably mediated by the caspase-3
apoptotic pathway triggered by mitochondrial calcium overload. The finding offers a new therapeutic candidate for early brain
injury after SAH.
1. Introduction
Subarachnoid hemorrhage (SAH), accounting for 5% of all
strokes, is a fatal disease with high morbidity and mortality,
and most cases result from the rupture of intracranial
aneurysm [1]. Early brain injury (EBI) is considered as the
primary cause of mortality as well as the deciding factor to
prognosis for survivors [2].
Many pathological processes are involved after the initial
hemorrhage such as apoptosis, oxidative stress, and impaired
calcium homeostasis [3]. Cell apoptosis plays a dominant
role in developing EBI after SAH [4]. This process is prob-
ably triggered by the mitochondrial injury [5]. Overload-
ing Ca2+ is commonly known as one of the indicators of
mitochondrial injury [6]. It could initiate amolecular cascade
that culminates in cell apoptosis [7], including promoting
the depolarization of the mitochondria, then releasing sec-
ond mitochondria-derived activator of caspases (Smac) and
cytochrome c (cyt c) to the cytoplasm, enhancing caspase 3,
and finally activating deoxyribonuclease (DNase) to degrade
DNA of the neurons [6, 8]. At the same time, the release
of cyt c can increase the production of B-cell lymphoma
2 (bcl-2), to inhibit the initiation of cell apoptosis [6, 9,
10]. Therefore, ameliorating mitochondrial injury could be a
promising therapeutic target for early brain injury after SAH.
Chuanxiong rhizome (scientific name: Ligusticum
chuanxiong Hort.; Chinese name: chuanxiong) has been
widely used to treat cerebrovascular diseases with a long
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history in China [11]. Tetramethylpyrazine (TMP), an active
ingredient extracted from chuanxiong rhizome, demon-
strates a broad therapeutic capacity such as scavenging
oxygen free radicals, reducing the migration of circulatory
leukocytes, downregulating proinflammatory cytokine pro-
duction, and regulating the NO/cGMP signaling [12–16].
In animal models with cerebral or spinal cord ischemia,
TMP reduces cerebral infarct volumes, which is probably
mediated by rescuing neuronal apoptosis [12, 13, 17–19]. This
antiapoptotic effect is associated with downregulating the
expressions of bcl-2 and Bcl-2 Associated X Protein (bax)
alongside with suppressing caspase-3 [12].
In the animal model with SAH, TMP inhibits cell apop-
tosis as well, which is related to reducing caspase-3 in the
cytoplasm [20]. However, it remains uncertain whether this
effect has a relationship with rescuing mitochondrial dys-
function though TMP relieves mitochondrial impairments
in other animal models [21]. Therefore, we hypothesized
that the antiapoptotic effect of TMP was associated with
altering the mitochondrial-dependent caspase-3 apoptotic
pathway. To validate this hypothesis, we conducted the neu-
robehavioral assessment of the SAH rats treated by TMP and
measuredmitochondrial and cytoplasmicCa2+ accumulation
and mitochondrial membrane potential changes alongside
with proteins expressed in the following caspase-3 apoptotic
pathway.
2. Materials and Methods
All procedures were conducted in accordance with the UK
Animals (Scientific Procedures) Act 1986 and associated
guidelines, the EEC Directive of 1986 (86/609/EEC), the
NIH guide for the care and use of laboratory animals (NIH
Publication number 80-23; revised 1978), the Regulations
for the Administration of Affairs concerning Experimental
Animals released by the State Council of the People’s Republic
of China (number 2, 1988), and Guidelines for the Care and
Use of Laboratory Animals published by Ministry of Science
and Technology of the People’s Republic of China (number 2,
1988).
2.1. Animal Preparation and Grouping. Adult male Wistar
rats (300 g–330 g) were obtained from the Animal Center,
Yangzhou University. All rats were housed in 12 h dark/light
cycle room with the average temperature of 25∘C, and they
were allowed free access to food and water. Seventy-five rats
were randomly allocated to three groups, including SAH
model treated with TMP (𝑛 = 25), SAH model treated with
saline (𝑛 = 25), and the sham-operation group without any
treatments (𝑛 = 25).
2.2. SAH Model. As previously described [22], the SAH
model was established by injecting autologous blood to
prechiasmatic cistern of the rats. First, the Wistar rats were
anesthetized with chloral hydrate (400mg/kg, IP). Then
300 𝜇L bloodwas drawn from the right femoral arterywith an
insulin syringe (1mL 29G × 1/2m, 0.33mm × 12.7mm) (BD
Science, US). A midline scalp incision was made and a 1mm
hole was drilled 8.0mm anterior to the bregma in themidline
of the skull without brain injury. Subsequently, the needle
of the syringe was advanced 11mm at a 45∘ angle into the
prechiasmatic cistern through the burr hole. The procedure
in the sham-operation group was identical except saline was
injected instead. The SAH model was confirmed by autopsy.
2.3. Treatments. TMP was obtained from Shanghai Yuanye
Bio-Technology, Shanghai, China (number KM0513CA14).
It was dissolved in saline water. TMP at 30mg/kg was
administrated by intraperitoneal injection 15 minutes after
the experimental SAH because this treatment was proven
to inhibit the caspase-3 [20] though effective doses of TMP
for ischemia varied (10mg/kg to 160mg/kg) [12, 19, 23]. As
a control group, 3mL saline was injected to the SAH rats
instead.
2.4. Neurobehavioral Assessment. Neurobehavioral assess-
ment containing appetite, activity, and neurological deficits
was conducted 24 hours after the experimental SAH [8]. Four
grades of impairments were assigned to the rats according to
the total scores, including no impairment (score = 0), slight
impairment (scores ≤ 2), moderate impairment (scores = 3∼
4), and severe impairment (scores≥ 5).The assessorwas blind
to the treatment allocations.
2.5. Brain Tissue Preparation. After the behavioral assess-
ment, the rats were sacrificed by intracardial perfusion with
saline at 4∘C.Then temporal lobes were isolated after clearing
blood clots. These tissues were used, respectively, for mor-
phological observation, measurement of Ca2+ concentration,
Western blot, and TUNEL assay.
2.6. Morphological Observation on Mitochondria. As previ-
ously described, the sample for morphological observation
was prepared [8]. The temporal lobes tissues were fixed with
2.5% buffered glutaraldehyde for 2 hours and then minced
into smaller fragments (0.5mm × 0.5mm × 1mm). Next,
the tissues were fixed with glutaraldehyde for 1 hour and
with 1% OsO
4
in the same buffer for 1 hour. Then they
were dehydrated with alcohol and embedded in araldite.
The semithin (300 nm) sections were prepared and then
stained with 1% toluidine blue in distilled water at 60∘C.
Later the sections were trimmed over the neurons to order
to gain an overview of the mitochondria of interest under
light microscopy. Next, the ultrathin sections (60 nm) were
prepared and mounted on nickel grids. The sections were
then observed using the Transmission Electron Microscopy
JEM-1011 (JEOL, Japan), after being stained with lead citrate
and uranyl acetate.
2.7. Mitochondria Isolation and Ca2+ Measurement. Mito-
chondria and cytoplasmic fractions were isolated from the
temporal lobes using the Mitochondria Isolation Kit for
Tissue (Beyotime, China). Next, the Ca2+ in cytoplasm and
mitochondria were, respectively, detected by the Cytoplas-
mic Ca2+ Concentration Quantitative Determination Kit
(Genmed, USA) and the Mitochondrial Ca2+ Concentration
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Quantitative Determination Kit (Genmed, USA). Then the
fluorescence microplate reader was used to quantify the Ca2+
concentration.
2.8. Measurement of Mitochondrial Membrane Potential.
Reduction in mitochondrial membrane potential (Δ𝜓m) is
an indicator for mitochondrial and cellular dysfunction [9].
The Δ𝜓m was detected using JC-1 Mitochondrial Membrane
Potential Assay Kit (Beyotime, China). The intensities of red
(excitation/emission wave length = 525/590 nm) fluorescence
and green (excitation/emission wave length = 490/530 nm)
were quantified by the Olympus IX51 inverted microscope
system (Olympus, Japan). Then the Δ𝜓m was indicated by a
decrease in the red/green fluorescence intensity ratio.
2.9. Western Blotting Analysis. A release of cyt c and second
mitochondria-derived activator of caspases (Smac) from
injured mitochondria into the cytosol and an increase in
cleaved caspase-3 indicate cellular apoptosis. The increase of
bcl-2, the apoptosis inhibitor, suggests the protection against
apoptosis [6, 11, 12]. Therefore, we measured the expression
of cyt c, Smac, cleaved caspase-3, and bcl-2 to determine the
effect of treatments on cellular apoptosis.
The brain tissues without mitochondria were used to
determine the expressions of cyt c and Smac in the cyto-
plasm while parts of the fresh temporal lobes were used to
determine the expressions of bcl-2 and cleaved caspase-3. As
previously described [24], the procedure of Western blot was
followed. After being homogenized in lysis buffer (Thermo
Fisher Scientific, USA), the brain tissues were centrifuged at
14,000×g for 15 minutes at 4∘C and then the supernatants
were collected. Equal amount of protein (30 𝜇g per lane)
was resolved by 2x sodium dodecyl sulfate (SDS) with
heating and electrophoresis and then transferred onto the
nitrocellulosemembrane sheets. After being blocked with 5%
nonfat milk for 90 minutes at room temperature, the sheets
were incubated overnight at 4∘C with primary antibodies
against cyt c (1 : 1000, Abcam, UK), cleaved caspase-3 (1 : 500,
Cell Signaling Technology, USA), bcl-2 (1 : 1000, Santa Cruz
Biotech, USA), Smac (1 : 1000, Cell Signaling Technology,
USA), and the loading control GAPDH (1 : 5000, Abcam,
UK).Then themembraneswerewashedwithTween 20 inTris
buffered saline (TTBS, 100mMTris–HCl, pH 7.5, 0.9% NaCl,
0.1% Tween 20). After being incubated with secondary anti-
bodies and washed again, the immunoreactive polypeptide
bands were visualized by the Enhanced Chemiluminescence
Western blot Detection Reagents (Thermo Fisher Scientific,
USA) and their densities were quantified by the Automatic
Chemiluminescence Imaging Analysis System (Tanon-5200,
Tanon, China). The changes of protein expression were
calculated as target protein expression/GAPDH expression
ratio.
2.10. TUNEL Staining. A part of temporal lobes was sliced
after being fixed with 4% paraformaldehyde and then it was
dehydrated by saccharose phosphate-buffered saline (PBS).
TUNEL assay was conducted using the In Situ Cell Death
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Figure 1: Neurological impairment numbers of animals after SAH.
There was no statistical difference between the SAH + TMP group
and SAH + Vehicle group (𝜒2 = 0.936, 𝑃 = 0.52) (𝑛 = 25 in
each group) although there was a trend that TMP resulted in less
neurological impairment.
Detection Kit (Roche, USA). The slices were counterstained
by 4󸀠,6-diamidino-2-phenylindole (DAPI, Beyotime, China)
and covered by Antifade Mounting Medium (Beyotime,
China). Fluorescence microscopy images were observed by
the Olympus IX51 inverted microscope system (Olympus,
Japan). Apoptosis index (AI) was defined as the mean
percentage of TUNEL-positive cells out of six cortical micro-
scopic fields (×400 magnification). The relevant personnel
were blind to treatment assignments.
2.11. Statistical Analysis. The continuous data was presented
as mean ± SD and one-way ANOVA followed by Bonferroni
correction test was used to analyze the group difference.
In terms of the neurobehavioral impairment, the ordinal
outcomewas transferred to a dichotomous outcome, effective
rate, by dividing the SAH rats into two groups, including
those with no or slight impairments and those withmoderate
or severe impairments and then Chi-square test or Fisher
exact test was applied to analyze the group difference. A 𝑃
value of less than 0.05 was considered statistical significance.
The statistical analysis was performed using IBM SPSS
Statistics 24.0 and the figures were drawn using GraphPad
Prism software 6.0.
3. Results
3.1. Neurobehavioral Impairment. None of the rats died or
suffered from neurobehavioral impairments in the sham-
operation group as well as blood clots around basilar arteries
and temporal lobes (Figure 1). There was no statistical differ-
ence of the effective rate between the SAH group treated with
TMP and that with saline (𝜒2 = 0.936, 𝑃 = 0.52) although
there was a trend that TMP resulted in less neurological
impairment.
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(a) (b) (c)
Figure 2: Electron photomicrographs of mitochondria after SAH and protective effects of TMP. (a) A mitochondrion with normal shape
from the sham-operation group. (b) Swelling mitochondria with collapsed cristae, disruptive membranes from the SAH + Vehicle group. (c)
Mitochondria with much better shape from the SAH + TMP group. Scale bar indicates 0.5𝜇m.
Table 1: Ca2+ concentration in the cytoplasm and mitochondria.
Cytoplasmic Ca2+
(10−2 nmol/𝜇g)
Mitochondrial Ca2+
(10−2 nmol/𝜇g)
Sham-operation
group 24.03 ± 8.10 78.69 ± 6.46
SAH + Vehicle group 237.94 ± 15.13∗ 281.47 ± 19.82∗
SAH + TMP group 81.95 ± 11.26# 179.96 ± 20.11#
Note. Data represent the means ± SD of 3 groups (n = 5 in each group)
(∗𝑃 < 0.05 versus sham-operation group; #𝑃 < 0.05 versus SAH group with
vehicle).
3.2.Morphological Observations forMitochondria. The trans-
mission electron microscopy found normal shape, intact
membrane and cristae, and dense matrix space for the
mitochondria in the sham-operation group (Figure 2(a)).
In the SAH group treated with saline, the mitochondria
swelled irregularly, mitochondrial vacuoles appeared, and
the membrane and cristae fractured and became fuzzy (Fig-
ure 2(b)). In the SAH group treated with TMP, the injuries of
mitochondria such as swelling and fracture appeared milder
than the group treated with SAH (Figure 2(c)).
3.3. Cytoplasmic and Mitochondrial Ca2+ Concentrations.
Ca2+ concentration in both cytoplasm and mitochondria
after experimental SAH greatly increased. Compared to the
SAH group treated with saline, lower concentration of Ca2+
in cytoplasm and mitochondria was found in the group
with TMP and these differences were statistically significant
(Table 1).
3.4. Mitochondrial Membrane Potential. Compared to the
sham-operation group (1.60±0.42), Δ𝜓m in the SAH treated
with saline group was significantly decreased, indicating
mitochondrial depolarization. Δ𝜓m in the SAH treated with
TMP (1.28 ± 0.19) was higher than that in the group with
saline (0.34 ± 0.01) and this difference was statistically
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Figure 3: Δ𝜓m of animals after SAH and protective effects of TMP.
Δ𝜓m decreased dramatically after SAH, which means depolariza-
tion of mitochondria. Treatment with TMP greatly alleviated the
decrease of Δ𝜓m. Data represent the mean ± SD of 3 groups (𝑛 = 5
in each group). (∗𝑃 < 0.05 versus sham-operation group; #𝑃 = 0.515
versus sham-operation group).
significant (𝑃 < 0.05). However, there was no statistical dif-
ference of Δ𝜓m between the sham-operation and the TMP
group (𝑃 = 0.515). (𝑛 = 5 in each group) (Figure 3).
3.5. Expressions of cyt c, Smac, Cleaved Caspase-3, and bcl-
2. Cyt c and Smac in cytoplasm and cleaved caspase-3 in
the SAH with saline group were much higher than those
in the sham-operation group. Compared to the SAH group
treated with saline, the expressions of these proteins were
much lower in the groupwithTMPand these differenceswere
statistical significant.The expression of bcl-2 wasmuch lower
in the SAH with saline group or TMP group than the sham-
operation group. However, the differences of cyt c, Smac,
cleaved caspase-3, and bcl-2 were statistically significant
between the TMP group and the sham-operation group.
Figure 4 detailed the representative images from Western
blotting analysis and the statistical results.
Evidence-Based Complementary and Alternative Medicine 5
cleaved-caspase-3
Cyto-cyt c
Cyto-Smac
bcl-2
GAPDH
Sham SAH +
Vehicle
SAH +
TMP
15kDa
21kDa
17kDa
26kDa
37kDa
(a)
Sham SAH + Vehicle SAH + TMP
0
5
10
15
#
∗
Re
la
tiv
e i
nt
en
sit
y
(c
yt
o-
cy
t c
/G
A
PD
H
)
(b)
Sham SAH + Vehicle SAH + TMP
0
2
4
6
#
∗
Re
la
tiv
e i
nt
en
sit
y
(c
yt
o-
Sm
ac
/G
A
PD
H
)
(c)
Re
la
tiv
e i
nt
en
sit
y
(c
le
av
ed
 ca
sp
as
e-
3/
G
A
PD
H
)
Sham SAH + Vehicle SAH + TMP
0
2
4
6
8
#
∗
(d)
Sham SAH + Vehicle SAH + TMP
0.0
0.5
1.0
1.5
#
∗
Re
la
tiv
e i
nt
en
sit
y
(b
cl-
2/
G
A
PD
H
)
(e)
Figure 4: Expressions of cyt c and Smac, cleaved caspase-3, and bcl-2. (a) forWestern blotting images; (b) for cyt c in different groups; (c) for
Smac; (d) for cleaved caspase-3; (e) for bcl-2.The bar graph shows the ratio of the cyt c, Smac, cleaved caspase-3, and bcl-2 integrated density
value (IDV) to GAPDH IDV for each experimental condition. Data represent the mean ± SD of 3 groups (𝑛 = 5 in each group). As figures
showed, the increase of cytoplasmic cyt c and Smac took place after SAH and it was significantly inhibited by TMP treatment. Sham for sham-
operation group; SAH for subarachnoid hemorrhage; TMP for tetramethylpyrazine; GAPDH for glyceraldehyde 3-phosphate dehydrogenase;
cyt c for cytochrome c; Smac for second mitochondria-derived activator of caspases; bcl-2 for B-cell lymphoma 2. (∗𝑃 < 0.05 compared with
the sham-operation group, #𝑃 < 0.05 compared with the SAH + Vehicle group.)
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3.6. TUNEL-Positive Cells. Figures 5(a)–5(i) showed the
representative microphotographs of DAPI-positive cells,
TUNEL-positive cells and the merging.The apoptotic cells in
the SAH with saline group dramatically increased compared
to the sham-operation group.The apoptosis index (AI) which
was the TUNEL-positive cells/DAPI-positive cells ratio in the
SAH with TMP group was much less than that in the group
with saline and this difference was statistically significant
(𝑃 < 0.05); However, TMP group resulted in higher AI than
the sham group (Figure 5(j)). (𝑛 = 5 in each group).
4. Discussion
Cell apoptosis after SAH is one of the predominant mech-
anisms in developing EBI [10, 24]. Although the benefit of
TMP to cellular apoptosis for cerebrovascular diseases is
determined in laboratory experiments [12, 19, 20, 25], only a
few are conducted in SAH animal models. Our study demon-
strates the protective effect of TMP against cell apoptosis
after experimental SAH, which is of significant therapeutic
implication. In addition, we investigated the impact of TMP
on the potential caspase-3 apoptotic pathway. We found that
the acute treatment of TMP could suppress the cyt c, Smac
and cleaved caspase-3, and apoptotic activators and elevated
bcl-2, the apoptotic inhibitor [26]. Also TMP resulted in
slightermitochondrial impairments, in terms ofmorphology,
calcium overloading, and Δ𝜓m. All these findings suggest
that the protective effect of TMP against cell apoptosis after
SAH is probably associated with mitochondrial-dependent
caspase-3 apoptotic pathway, which provides additional pre-
clinical evidence of TMP for SAH. However, the treatment
TMP did not show significant superiority to saline in terms
of neurobehavioral functioning 24 hours after SAH though
it potentially resulted in better performance. Considering the
dose-dependent effect of TMP for ischemia [12, 22], further
studies investigating TMP in higher dosage are needed.
A previous study revealed that pretreatment of TMP
reduced caspase-3 in the SAH model [20]. However, preven-
tion from EBI is inconsistent with clinical practice as SAH
often attacks patientswith aneurysm suddenly [1]. Instead, we
treated SAHwith TMP 15 minutes after establishing the SAH
model. Therefore, the preclinical evidence generated from
our study is more probably to be transferred to the clinical.
Mitochondria are considered one of the major organelles
involved in cell apoptosis [27]. Ca2+ overloading in mito-
chondria and the subsequent depolarization of Δ𝜓m are the
key indicators of mitochondrial injury [6]. A considerable
amount of evidence found rapid Ca2+ influx right after the
aneurysm rupture and Ca2+ overloading was at the very early
stage of the mitochondrial injury [6]. Therefore, blocking
Ca2+ overloading may avoid initiating the apoptotic cascade
and further safeguard the patients from EBI [3, 28]. In
addition, the striking finding that TMP almost reversed
the mitochondrial depolarization suggested that TMP might
be a mitochondrial calcium channel blocker. It is recently
found that the Ca2+ uptake into mitochondria is mediated
by mitochondrial calcium uniporter (MCU), a unique ion
channel with high conductance and selectivity [29]. Our
previous study has demonstrated that the blockage of MCU
could reduce intracellular calcium overloading and thus
alleviate EBI after SAH [30]. Taken together, TMP is probably
a MUC blocker, which has never been reported though it
has been regarded as a calcium antagonist in smooth muscle
cell [31]. To further examine this possibility, other studies
such as observations of the structural changes of the MCU
and experimental use of MCU openers (e.g., polyamine like
spermine a) following the treatment of TMP are needed.
Caspase-3 is located at the final of apoptotic pathway [32].
It is often used as a representative activator for apoptosis. It
would be more valuable to determine whether TMP could
reverse the upstream impairment of caspase-3 level. Smac is a
major determinant in themitochondria-dependent apoptotic
pathway. It can drive or amplify the release of cyt c and
following cyt c further elevate the production of caspase-3
[33, 34]. Our study found TMP could suppress cyt c, Smac,
and caspase-3, which implied that TMP could also ameliorate
the earlier commencement of the apoptosis. But the releasing
of mitochondrial Smac is often suppressed by bcl-2 [26]. Our
study also found the enhancement of bcl-2 after the treatment
of TMP, which suggested the global impact of TMP on the
apoptotic pathway.
In addition to initiating cellular apoptosis, impaired
mitochondria may also lead to cellular necrosis due to the
depletion and insufficient generation of ATP and serious
influence on the normal cellular communication through
Ca2+ signals, particularly in the central nervous system [7,
35, 36]. Therefore TMP may also reverse cellular necrosis.
Other potential benefits of TMP may include reducing the
overproduction of reactive oxygen species, ameliorating cel-
lular inflammatory response, andmaintaining vasorelaxation
by enhancing eNOS [19, 37, 38].
In clinical settings, nimodipine is the only drug approved
for SAH; however, its effectiveness on neurological perfor-
mance is unsatisfactory although a series of high-quality
evidences indicate its therapeutic potential in vasospasm [39,
40]. Clinical studies have suggested the dissociation between
vasospasm and neurological functions [41]. According to our
best knowledge, up to now there is no successful neuropro-
tective drug for SAH [42]. TMP could be a promising new
drug candidate for SAH.
Limitations include the uncertain identity of the apop-
totic cell andmitochondria. Further evaluation on antibodies
against neuronal marker neuronal nuclear protein (NeuN)
and astrocyte marker glial fibrillary acidic protein (GFAP)
following the analysis of the TUNEL-positive cells is needed
[43]. Cellular identity of mitochondria is also required as the
mitochondria in our research may come from neurons or
astrocytes.
5. Conclusions
TMP could suppress the mitochondrial apoptosis-relative
pathway after SAH. These results suggest that TMP may be
a new neuroprotectant for the treatment of SAH.
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Figure 5: TUNEL-positive and apoptosis index. (a–c) Representative microphotographs of DAPI-positive cells (blue dots); (d–f)
representative microphotographs of TUNEL-positive cells (green dots); (g–i) representative microphotographs merging DAPI-positive cells
and TUNEL-positive cells. (j) Apoptosis index (AI) was defined as the mean percentage of TUNEL-positive cells out of all DAPI-positive
cells in six cortical microscopic fields (×400 magnification). As figures showed, the apoptosis triggered by SAH was improved by TMP. Bars
represent the mean ± SD (𝑛 = 5 in each group) (∗𝑃 < 0.05 compared with the sham-operation group, #𝑃 < 0.05 compared with the SAH+
Vehicle group.) Scale bar indicates 20𝜇m.
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